Search
Deborah Hannah Lehmann Moore AO, MBBS, MSc OAM BSc (Hons) GradDipClinEpi PhD Honorary Emeritus Fellow Head, Infectious Diseases Research 08 6319 1427
Otitis media (OM, middle ear infections) and the consequent hearing loss are major concerns for Aboriginal people and OM can seriously impact on children’s learning potential which in turn will impact on life as an adult.
A telehealth-facilitated randomised-controlled trial utilising a health promotion intervention to resolve otitis media with effusion for children won specialist Ear, Nose and Throat (ENT) waiting lists
Deborah Peter Lehmann Richmond AO, MBBS, MSc MBBS MRCP(UK) FRACP Honorary Emeritus Fellow Head, Vaccine Trials Group Honorary Emeritus Fellow Head,
Deborah Lehmann AO, MBBS, MSc Honorary Emeritus Fellow Honorary Emeritus Fellow Clinical Associate Professor Deborah Lehmann is a medical
Chris Andrew Monique Sarra Videos Brennan-Jones Whitehouse Watch and listen to Andrew Robinson Jamieson PhD PhD PhD MPsych (Clin) MAPS BSc (Hons) MSc
The purpose of this study is to explore the effectiveness of a hospital-based asynchronous ear, nose, and throat telehealth service (the Ear Portal) in reducing cost and improving access for children with otitis media.
Chris Valerie Brennan-Jones Swift PhD Head, Ear and Hearing Health Aboriginal Co-Director, Djaalinj Waakinj Centre for Ear and Hearing Health;
Globally, Indigenous populations have been disproportionately impacted by pandemics. In Australia, though national infection rates with COVID-19 infections in Aboriginal and/or Torres Strait Islander people were lower in the first 12 months of the COVID-19 pandemic, there was soon a greater burden in Aboriginal and/or Torres Strait Island people once Omicron was circulating. Uptake of the COVID-19 vaccine was also lower among Aboriginal and/or Torres Strait Islander people.
In Australian remote communities, First Nations children with otitis media (OM)-related hearing loss are disproportionately at risk of developmental delay and poor school performance, compared to those with normal hearing. Our objective was to compare OM-related hearing loss in children randomised to one of 2 pneumococcal conjugate vaccine (PCV) formulations.